Vaccine-maker Bharat Biotech claimed that with several hundred million doses administered worldwide, Covaxin has demonstrated an excellent safety record with minimal adverse events and no vaccine associated cases detected for myocarditis or thrombocytopenia
Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.
On Friday, April 26, Congress leader Rahul Gandhi retaliated against Prime Minister Narendra Modi over his attack on the grand…
Climate change has not traditionally been seen as a health and human rights concern — but that may be changing…
Food loss after harvest has economic implications for the farmer and also impacts the environment due to loss of agricultural…
The global market for e-bikes is surging. These bicycles, usually equipped with pedals and an electric motor assist, are popular…
A new study that analysed consumption data in India found stark differences in the water, particulate matter and carbon footprints…
We’ve all heard about climate change’s effect on our planet — but do you know about the many ways it…
This website uses cookies.